Executive summary Prostate cancer is the most common cancer in men in 112 countries,
and accounts for 15% of cancers. In this Commission, we report projections of prostate …

In response to the rising incidence of indolent, low-risk prostate cancer (PCa) due to
increased prostate-specific antigen (PSA) screening in the 1990s, active surveillance (AS) …

Many men diagnosed with localized prostate cancer can postpone definitive treatment
without raising their risk of metastasis or death from disease. Active surveillance (AS) is a …

Introduction Active surveillance (AS) has been widely adopted for the management of men
with low-risk prostate cancer. However, there is still a lack of consensus surrounding the …

Prostate cancer is a heterogeneous cancer with widely varying levels of morbidity and
mortality. Approaches to prostate cancer screening, diagnosis, surveillance, treatment and …

Background/Aim: To evaluate the diagnostic accuracy of the urinary SelectMDx test in the
diagnosis of clinically significant prostate cancer (csPCa) in men enrolled in an active …

Purpose: Few validated clinical tools currently exist to standardize the frequency of biopsies
for men on active surveillance for low risk prostate cancer. We determined predictors of …

For men with newly diagnosed prostate cancer, we aimed to develop and validate a model
to predict the risk of progression on active surveillance (AS), which could inform more …

Introduction Active surveillance (AS) is considered a suitable management practice for those
patients with low‐risk prostate cancer (PCa). At present, however, the role of multiparametric …

Background: Evaluation of the feasibility for osteopontin (OPN) to serve as a biomarker in
the prognosis and clinical-pathological features of prostate cancer (PCA) patients. Methods …